Actively Recruiting
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Led by AbbVie · Updated on 2026-05-13
48
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
CONDITIONS
Official Title
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI between 30.0 and 45.0 kg/m2 at screening
- Female participants must not be pregnant or breastfeeding
- Female participants must not plan to become pregnant or donate eggs during the study or for 60 days after the last dose
You will not qualify if you...
- Weight change of 5% or more within 3 months before screening
- HbA1c of 6.5% or higher and/or serum glucose of 126 mg/dL or higher at screening
- Use of medication to treat obesity or participation in an obesity trial within 180 days before study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Acpru /Id# 278624
Grayslake, Illinois, United States, 60030
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here